KR101841866B1 - N-[(3-아미노옥세탄-3-일)메틸]-2-(1,1-디옥소-3,5-디하이드로-1,4-벤조티아제핀-4-일)-6-메틸-퀴나졸린-4-아민의 제조 방법 - Google Patents

N-[(3-아미노옥세탄-3-일)메틸]-2-(1,1-디옥소-3,5-디하이드로-1,4-벤조티아제핀-4-일)-6-메틸-퀴나졸린-4-아민의 제조 방법 Download PDF

Info

Publication number
KR101841866B1
KR101841866B1 KR1020167020106A KR20167020106A KR101841866B1 KR 101841866 B1 KR101841866 B1 KR 101841866B1 KR 1020167020106 A KR1020167020106 A KR 1020167020106A KR 20167020106 A KR20167020106 A KR 20167020106A KR 101841866 B1 KR101841866 B1 KR 101841866B1
Authority
KR
South Korea
Prior art keywords
formula
acid
compound
temperature range
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167020106A
Other languages
English (en)
Korean (ko)
Other versions
KR20160102055A (ko
Inventor
준리 천
이 런
진 셔
린 왕
지옌화 유
구오차이 장
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20160102055A publication Critical patent/KR20160102055A/ko
Application granted granted Critical
Publication of KR101841866B1 publication Critical patent/KR101841866B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020167020106A 2014-01-24 2015-01-21 N-[(3-아미노옥세탄-3-일)메틸]-2-(1,1-디옥소-3,5-디하이드로-1,4-벤조티아제핀-4-일)-6-메틸-퀴나졸린-4-아민의 제조 방법 Active KR101841866B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/071331 2014-01-24
CNPCT/CN2014/071331 2014-01-24
PCT/EP2015/051066 WO2015110446A1 (en) 2014-01-24 2015-01-21 Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine

Publications (2)

Publication Number Publication Date
KR20160102055A KR20160102055A (ko) 2016-08-26
KR101841866B1 true KR101841866B1 (ko) 2018-03-23

Family

ID=52358790

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167020106A Active KR101841866B1 (ko) 2014-01-24 2015-01-21 N-[(3-아미노옥세탄-3-일)메틸]-2-(1,1-디옥소-3,5-디하이드로-1,4-벤조티아제핀-4-일)-6-메틸-퀴나졸린-4-아민의 제조 방법

Country Status (20)

Country Link
US (2) US10005770B2 (cg-RX-API-DMAC7.html)
EP (2) EP3248969B1 (cg-RX-API-DMAC7.html)
JP (1) JP6397501B2 (cg-RX-API-DMAC7.html)
KR (1) KR101841866B1 (cg-RX-API-DMAC7.html)
CN (2) CN109879837B (cg-RX-API-DMAC7.html)
AR (2) AR099134A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015208244B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016016978B1 (cg-RX-API-DMAC7.html)
CA (1) CA2934225C (cg-RX-API-DMAC7.html)
ES (2) ES2788900T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20200715T1 (cg-RX-API-DMAC7.html)
IL (1) IL245882B (cg-RX-API-DMAC7.html)
MX (1) MX368110B (cg-RX-API-DMAC7.html)
MY (1) MY176210A (cg-RX-API-DMAC7.html)
NZ (1) NZ721534A (cg-RX-API-DMAC7.html)
PL (2) PL3097098T3 (cg-RX-API-DMAC7.html)
RU (1) RU2664643C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201605916QA (cg-RX-API-DMAC7.html)
SI (2) SI3097098T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015110446A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
WO2017009316A1 (en) 2015-07-16 2017-01-19 F. Hoffmann-La Roche Ag Crystalline forms of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1 -dioxido-1,4-benzothiazepin-4(5 h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections
MY197231A (en) 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
CA3119019C (en) 2015-12-10 2024-06-11 Ptc Therapeutics, Inc. Compounds and methods for treating huntington's disease
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
CN108017599B (zh) * 2016-11-04 2020-03-03 上海爱科百发生物医药技术有限公司 [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CN111386118B (zh) 2017-09-29 2023-05-09 英安塔制药有限公司 作为rsv抑制剂的组合药物剂
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
WO2020190935A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
CA3139821A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
PH12022550783A1 (en) 2019-10-04 2023-07-31 Enanta Pharm Inc Antiviral heterocyclic compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
WO2021083290A1 (en) 2019-10-31 2021-05-06 Shanghai Ark Biopharmaceutical Co. Ltd. Respiratory syncytial virus fusion protein inhibitor compositions and methods for the treatment and prophylaxis of rsv diseases using the same
CN113149977A (zh) * 2020-01-22 2021-07-23 苏州爱科百发生物医药技术有限公司 一类呼吸道合胞病毒抑制剂的合成与用途
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
CN111548325A (zh) * 2020-05-16 2020-08-18 西安都创医药科技有限公司 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用
CN111518055A (zh) * 2020-05-16 2020-08-11 西安都创医药科技有限公司 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用
CN111620838A (zh) * 2020-05-16 2020-09-04 西安都创医药科技有限公司 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用
CN111574475B (zh) * 2020-06-03 2022-09-20 西安都创医药科技有限公司 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2023009961A (es) 2021-02-26 2023-09-05 Enanta Pharm Inc Compuestos heterociclicos antivirales.
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds
EP4745139A1 (en) * 2023-07-10 2026-05-20 CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. COMPOUND FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES CAUSED BY THE RESPIRATORY SYNCYTIAL VIRUS
WO2026149524A1 (zh) * 2025-01-09 2026-07-16 石药集团中奇制药技术(石家庄)有限公司 氨基吡咯烷类衍生物及其制备方法和用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013020993A1 (en) 2011-08-11 2013-02-14 F. Hoffmann-La Roche Ag Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
WO2013053658A1 (en) 2011-10-11 2013-04-18 F. Hoffmann-La Roche Ag Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
WO2014184163A1 (en) 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383409A (en) * 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
SE9901573D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
CA2516329A1 (en) * 2003-02-21 2004-09-02 Pharmacia & Upjohn Company Llc Exo-(t-butyl 2r(+))-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate, intermediates, and process to prepare and isolate them
US20050009817A1 (en) * 2003-04-30 2005-01-13 Jennifer Savoy Substituted heteroaryls
DE102004045648A1 (de) * 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
JP4899385B2 (ja) * 2005-09-06 2012-03-21 宇部興産株式会社 3−アミノメチルオキセタン化合物の製法
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP2013534233A (ja) * 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的jak阻害剤としてのヘテロシクリルピラゾロピリミジン類似体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013020993A1 (en) 2011-08-11 2013-02-14 F. Hoffmann-La Roche Ag Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
WO2013053658A1 (en) 2011-10-11 2013-04-18 F. Hoffmann-La Roche Ag Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
WO2014184163A1 (en) 2013-05-14 2014-11-20 F. Hoffmann-La Roche Ag Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection

Also Published As

Publication number Publication date
CA2934225A1 (en) 2015-07-30
JP2017503843A (ja) 2017-02-02
CN106414436A (zh) 2017-02-15
MX2016009514A (es) 2016-10-26
IL245882B (en) 2019-09-26
PL3248969T3 (pl) 2020-06-29
KR20160102055A (ko) 2016-08-26
AR118371A2 (es) 2021-09-29
AU2015208244A1 (en) 2016-06-16
CN106414436B (zh) 2019-04-23
SI3097098T1 (sl) 2020-07-31
RU2016133187A3 (cg-RX-API-DMAC7.html) 2018-02-28
EP3097098B1 (en) 2020-03-04
US10005770B2 (en) 2018-06-26
HRP20200715T1 (hr) 2020-07-24
US10253022B2 (en) 2019-04-09
EP3097098A1 (en) 2016-11-30
BR112016016978B1 (pt) 2022-08-16
NZ721534A (en) 2018-02-23
JP6397501B2 (ja) 2018-09-26
MY176210A (en) 2020-07-24
RU2016133187A (ru) 2018-02-28
BR112016016978A2 (cg-RX-API-DMAC7.html) 2017-08-08
SI3248969T1 (sl) 2020-07-31
MX368110B (es) 2019-09-18
EP3248969A1 (en) 2017-11-29
US20180265505A1 (en) 2018-09-20
PL3097098T3 (pl) 2020-06-29
IL245882A0 (en) 2016-08-02
ES2788900T3 (es) 2020-10-23
EP3248969B1 (en) 2020-03-04
AU2015208244B2 (en) 2017-11-02
US20160326160A1 (en) 2016-11-10
HRP20200680T1 (hr) 2020-07-24
ES2789798T3 (es) 2020-10-26
RU2664643C2 (ru) 2018-08-21
CA2934225C (en) 2018-09-04
AR099134A1 (es) 2016-06-29
CN109879837A (zh) 2019-06-14
SG11201605916QA (en) 2016-08-30
WO2015110446A1 (en) 2015-07-30
CN109879837B (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
KR20160102055A (ko) N-[(3-아미노옥세탄-3-일)메틸]-2-(1,1-디옥소-3,5-디하이드로-1,4-벤조티아제핀-4-일)-6-메틸-퀴나졸린-4-아민의 제조 방법
US6576786B2 (en) Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof
CN114728923B (zh) 用于制备氧杂环丁烷-2-基甲胺的方法和中间体
JP2025061453A (ja) 1,5-ベンゾチアゼピン化合物を製造するための方法
JP2023536207A (ja) フタラジノン誘導体及びその中間体を調製するプロセス
HK1231875A1 (en) Process for the preparation of compound for prophylaxis and treatment of rsv
US9067868B2 (en) Chemical process for opening ring compounds
WO2020031040A1 (en) Process and intermediates for the preparation of boc-linagliptin
HK1231875B (en) Process for the preparation of compound for prophylaxis and treatment of rsv
US20240343689A1 (en) Synthesis of brivaracetam
JP4238978B2 (ja) ベンゾアゼピン化合物及びその製造法

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20160722

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160722

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170620

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20171219

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180319

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180319

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20211229

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240226

Start annual number: 7

End annual number: 7